Clinical Trials Browser

Phase 1 × Terminated × Breast × Clear all

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06878248 2026-05-28

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Phase 1 Terminated

10 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Phase 1 Terminated

154 enrolled

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT04931823 2026-04-03

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Phase 1 Terminated

34 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04234113 2026-03-27

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Phase 1 Terminated

115 enrolled 43 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04504331 2026-02-12

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Phase 1 Terminated

4 enrolled 11 charts

Breast

Breast Neoplasms

NCT03237572 2026-02-09

Breast-48

Phase 1 Terminated

13 enrolled 10 charts

Breast

Breast Neoplasms

NCT05194072 2026-01-09

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Phase 1 Terminated

250 enrolled

BreastGastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Adenoid Cystic, Fallopian Tube Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03746431 2026-01-07

A Phase 1 Study of [225Ac]-FPI-1434 Injection

Phase 1 Terminated

78 enrolled

BreastDermatologicEndocrineGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Adrenocortical Carcinoma, Triple Negative Breast Neoplasms

NCT03955640 2025-12-22

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Phase 1 Terminated

3 enrolled

Breast

Breast Neoplasms

NCT05035407 2025-12-02

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Phase 1 Terminated

36 enrolled 7 charts

Breast

Carcinoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Phase 1 Terminated

17 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02936102 2025-11-14

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1 Terminated

154 enrolled

BreastSarcoma

Chordoma, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

NCT05252390 2025-11-06

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

82 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT06336148 2025-10-15

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Phase 1 Terminated

10 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04982926 2025-10-14

A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

Phase 1 Terminated

29 enrolled

BreastCNSThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma

NCT06264921 2025-09-25

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

Phase 1 Terminated

23 enrolled

BreastGastrointestinalGynecologicThoracic

Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Uterine Diseases, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05385705 2025-09-22

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Phase 1 Terminated

2 enrolled

Breast

Breast Neoplasms

NCT05013554 2025-09-15

Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

Phase 1 Terminated

44 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Neoplasms, Stomach Neoplasms

NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Terminated

94 enrolled 28 charts

BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

NCT05623488 2025-08-12

CAR T Cells in Mesothelin-Expressing Breast Cancer

Phase 1 Terminated

2 enrolled

Breast

Breast Neoplasms

NCT06299163 2025-07-23

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Phase 1 Terminated

11 enrolled

BreastDermatologicGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Adenocarcinoma of Lung, Mesothelioma, Malignant, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Leiomyosarcoma, Liposarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04042051 2025-07-22

Panthera

Phase 1 Terminated

2 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04116320 2025-07-14

AM-003

Phase 1 Terminated

5 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma

NCT03816839 2025-07-07

AMEERA-2

Phase 1 Terminated

10 enrolled

Breast

Breast Neoplasms

NCT05511844 2025-07-04

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Phase 1 Terminated

25 enrolled

Breast

HER2-positive Breast Cancer

NCT05274451 2025-07-01

A Study to Investigate LYL797 in Adults With Solid Tumors

Phase 1 Terminated

57 enrolled

BreastGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1 Terminated

33 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

17 enrolled

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT03742349 2025-05-18

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Phase 1 Terminated

64 enrolled

Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03596073 2025-05-07

Topical Calcipotriene Treatment for Breast Cancer Immunoprevention

Phase 1 Terminated

43 enrolled

Breast

Breast Neoplasms

NCT05067972 2025-05-06

C4431001

Phase 1 Terminated

30 enrolled 20 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00253318 2025-04-27

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

Phase 1 Terminated

15 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04209465 2025-04-17

MasterKey-01

Phase 1 Terminated

91 enrolled 26 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05576077 2025-03-10

STARLING

Phase 1 Terminated

31 enrolled

BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

6 enrolled

Breast

Breast Neoplasms

NCT05080842 2025-02-13

A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

Phase 1 Terminated

21 enrolled

Breast

Breast Neoplasms

NCT04254107 2025-02-10

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Phase 1 Terminated

133 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Triple Negative Breast Neoplasms

NCT06390241 2025-02-03

ARTHE

Phase 1 Terminated

18 enrolled

Breast

Breast Neoplasms

NCT02751528 2025-01-13

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Phase 1 Terminated

3 enrolled 10 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Breast Neoplasms, Male

NCT03092635 2025-01-06

AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy

Phase 1 Terminated

9 enrolled

Breast

Breast Neoplasms

NCT03549000 2024-12-13

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Phase 1 Terminated

127 enrolled

BreastGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04060862 2024-11-08

IPATunity150

Phase 1 Terminated

20 enrolled 11 charts

Breast

Breast Neoplasms

NCT03284723 2024-09-03

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

Phase 1 Terminated

95 enrolled 55 charts

Breast

Breast Neoplasms, Neoplasms

NCT02964507 2024-08-29

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Phase 1 Terminated

124 enrolled 23 charts

Breast

Breast Neoplasms, Neoplasms

NCT03674827 2024-08-23

Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

Phase 1 Terminated

36 enrolled 25 charts

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

49 enrolled 33 charts

BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT02876640 2024-06-18

Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

Phase 1 Terminated

27 enrolled 21 charts

Breast

Carcinoma, Intraductal, Noninfiltrating

NCT03621982 2024-06-13

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Phase 1 Terminated

78 enrolled 39 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Breast-48

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

A Phase 1 Study of [225Ac]-FPI-1434 Injection

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

CAR T Cells in Mesothelin-Expressing Breast Cancer

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Panthera

AM-003

AMEERA-2

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

A Study to Investigate LYL797 in Adults With Solid Tumors

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Topical Calcipotriene Treatment for Breast Cancer Immunoprevention

C4431001

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

MasterKey-01

STARLING

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

ARTHE

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

IPATunity150

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors